Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) shares reached a new 52-week high during trading on Wednesday after Cantor Fitzgerald raised their price target on the stock from $150.00 to $174.00. The stock traded as high as $127.71 and last traded at $127.02, with a volume of 35869 shares changing hands. The stock had previously closed at $122.88.
Several other research firms have also recently issued reports on SRPT. The Goldman Sachs Group boosted their target price on Sarepta Therapeutics from $152.00 to $171.00 and gave the stock a "buy" rating in a research report on Thursday, November 3rd. StockNews.com started coverage on Sarepta Therapeutics in a report on Wednesday, October 12th. They issued a "hold" rating on the stock. Robert W. Baird upped their price target on Sarepta Therapeutics from $110.00 to $152.00 in a report on Thursday, November 3rd. Morgan Stanley upped their price target on Sarepta Therapeutics from $135.00 to $141.00 and gave the stock an "equal weight" rating in a report on Thursday, October 13th. Finally, Royal Bank of Canada lowered their price target on Sarepta Therapeutics from $193.00 to $190.00 and set an "outperform" rating on the stock in a report on Thursday, November 3rd. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $148.09.
Get Sarepta Therapeutics alerts:Insider Buying and Selling at Sarepta Therapeutics
In other Sarepta Therapeutics news, Director Stephen Mayo sold 858 shares of the stock in a transaction on Thursday, November 17th. The stock was sold at an average price of $109.92, for a total transaction of $94,311.36. Following the transaction, the director now owns 6,387 shares of the company's stock, valued at approximately $702,059.04. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 6.40% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the business. Utah Retirement Systems lifted its stake in shares of Sarepta Therapeutics by 0.7% during the 3rd quarter. Utah Retirement Systems now owns 14,971 shares of the biotechnology company's stock worth $1,654,000 after purchasing an additional 100 shares during the period. Neuberger Berman Group LLC raised its position in shares of Sarepta Therapeutics by 2.5% in the 3rd quarter. Neuberger Berman Group LLC now owns 4,250 shares of the biotechnology company's stock worth $470,000 after buying an additional 105 shares during the period. Captrust Financial Advisors raised its position in shares of Sarepta Therapeutics by 3.1% in the 2nd quarter. Captrust Financial Advisors now owns 3,534 shares of the biotechnology company's stock worth $265,000 after buying an additional 107 shares during the period. Benchmark Investment Advisors LLC raised its position in shares of Sarepta Therapeutics by 2.9% in the 3rd quarter. Benchmark Investment Advisors LLC now owns 3,883 shares of the biotechnology company's stock worth $429,000 after buying an additional 110 shares during the period. Finally, Brinker Capital Investments LLC raised its position in shares of Sarepta Therapeutics by 3.6% in the 3rd quarter. Brinker Capital Investments LLC now owns 4,297 shares of the biotechnology company's stock worth $475,000 after buying an additional 150 shares during the period. Hedge funds and other institutional investors own 82.18% of the company's stock.Sarepta Therapeutics Stock Up 2.8 %
The company has a current ratio of 4.36, a quick ratio of 3.99 and a debt-to-equity ratio of 3.58. The firm has a market capitalization of $11.09 billion, a PE ratio of -15.39 and a beta of 1.08. The firm has a 50-day moving average of $113.63 and a two-hundred day moving average of $100.34.
Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last issued its earnings results on Wednesday, November 2nd. The biotechnology company reported ($2.94) earnings per share for the quarter, missing the consensus estimate of ($1.21) by ($1.73). The firm had revenue of $230.30 million during the quarter, compared to analysts' expectations of $234.55 million. Sarepta Therapeutics had a negative return on equity of 97.37% and a negative net margin of 81.76%. The company's quarterly revenue was up 21.6% compared to the same quarter last year. During the same period last year, the business posted ($0.60) earnings per share. On average, equities research analysts forecast that Sarepta Therapeutics, Inc. will post -8.21 EPS for the current year.
Sarepta Therapeutics Company Profile
(Get Rating)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.
Recommended Stories
- Get a free copy of the StockNews.com research report on Sarepta Therapeutics (SRPT)
- 3 Mid-Caps That Could Double in 2023
- Mullen Automotive Shares Jump After Signing New Partner
- REV Group Leads Specialty Vehicle Manufacturers Higher
- NVIDIA vs AMD: Which is better for 2023?
- We Are the Champions: 3 Dividend Growers Wall Street Loves
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.